Comparator mismatch across countries and subgroups
Your global value dossier uses Comparator A. The local HTA body evaluates against Comparator B. The health economics argument doesn’t hold for the local payer.
Why this happens
Local comparison logic differs from global
Global clinical trials typically compare against a single standard of care. But local payer bodies often use different comparators — a local generic, a different drug class, or a treatment sequence that reflects real-world prescribing in that country.
The mismatch is structural, not accidental. HTA bodies in France, Germany, and the UK routinely require head-to-head evidence against locally relevant alternatives. If your dossier doesn’t address their comparator, the submission stalls.
Without systematic comparator adaptation, market access teams end up building ad-hoc arguments that lack the rigour HTA committees demand.
“Our global dossier compared against standard of care. The local HTA wanted evidence against a specific biosimilar. We had nothing.”
— Head of Market Access, Nordics, Immunology
Sound familiar?
Typical situations we hear
01
HTA requires a different comparator
Your global trial compares against drug X. The local payer committee mandates comparison against drug Y, which dominates the local formulary.
02
No indirect comparison available
Direct head-to-head data doesn’t exist for the local comparator. You need a network meta-analysis — and time is running out.
03
Treatment sequence varies by market
In one market your drug is first-line; in another, it’s second-line. The value argument changes completely.
04
Biosimilar entry disrupts comparator landscape
A new biosimilar enters the market. The reference comparator in your dossier is no longer the relevant alternative for payers.
What breaks without intervention
The cost of doing nothing
HTA submission rejected or delayed
Without evidence against the locally relevant comparator, submissions are returned — adding 6–12 months to the reimbursement timeline.
Weak payer arguments at launch
Market access teams present global data to local payers. The disconnect undermines credibility.
Lost market share to adapted competitors
Competitors who invest in local comparator evidence secure reimbursement first.
How MAG solves it
From global data to local comparator logic
1
Comparator landscape mapping
We identify the locally relevant comparators for each target market — formulary data, prescribing patterns, HTA precedents, and treatment guidelines.
2
Gap analysis & evidence strategy
We assess what evidence exists and what needs to be generated or synthesized to build the local comparison.
3
Indirect comparison & data synthesis
Where direct head-to-head data is missing, we conduct matching-adjusted indirect comparisons (MAIC) or network meta-analyses.
4
Dossier adaptation & payer messaging
We restructure the value dossier around local comparator logic — with payer-ready language and objection-response matrices.
5
Multi-market coordination
For regional launches, we create a shared comparison framework adaptable to each market’s specific HTA requirements.
Services we use to solve this
What you get
Typical deliverables
Local comparator dossier
Indirect treatment comparison
Payer objection-response matrix
Budget impact model adaptation
HTA submission package
Formulary committee brief
Real work. Measurable outcomes.
Related case studies
Payer objection handling matrix for CDK4/6 inhibitor: country-specific HTA responses across CEE
✓ Objection-response pairs used in 4 successful reimbursement submissions
Read case study →
Biosimilar switching evidence dossier: immunogenicity and efficacy data for 6 EU market access submissions
✓ All 6 submissions supported with consistent evidence narrative
Read case study →
Frequently asked
Common questions
How do you identify the right local comparator?
We combine formulary analysis, prescribing data, published HTA decisions, and treatment guidelines to map the relevant comparator landscape per market.
Can you run indirect comparisons if no head-to-head data exists?
Yes. We conduct network meta-analyses (NMA), matching-adjusted indirect comparisons (MAIC), and simulated treatment comparisons.
Do you handle the health economics modeling?
We focus on the clinical evidence layer. For full pharmacoeconomic modeling, we collaborate with HEOR partners or your internal team.
What if the comparator changes mid-submission?
We build modular dossiers that can be updated with new comparator data without rebuilding the entire submission.
Still have questions about comparator adaptation?
Book a 20-minute scoping call. We’ll review your situation and suggest the fastest path forward.
Book a scoping call →
Browse all services
Need comparator-adapted
evidence for your market?
evidence for your market?
Tell us your target market and comparator challenge — we respond within 24 hours.
AI infrastructure
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.
Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Advisory board transcription + structured AI summary
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
// Query: biosimilar switching immunogenicity data 2023–24
search("trastuzumab biosimilar comparison", {
years: [2023, 2024],
output: "structured_table"
})
// 1,240 records → 31 relevant
Processing 1,240 records...
Comparator Evidence
CT-P13 biosimilar switch study (Lancet 2023): no clinically meaningful difference in ADA incidence (2.1% vs 2.3%, p=0.89). Extrapolation across indications supported...